Gathering data and analyzing it are processes that shape one another. Increasingly available clinical trial data empower skilled investigators to complement the activities of those who gathered the data through creative and unexpected analyses. Under some of the emerging scenarios of clinical trial data sharing, researchers wishing to conduct a novel analysis can do so without first earning endorsement from those who generated the data. The locus of control rests with the person or group with a novel analytical plan. This emerging reality has caused concern in some quarters and is seen as a reason to celebrate in others. To skeptics wondering whether important new analyses will bubble up in this new ecosystem of data sharing, I am pleased to say that the answer is definitively: 'Yes!' Randomized controlled trials (RCTs) are the most robust means of evaluating whether a treatment improves health. Nevertheless, like all research methods, RCTs have limitations. At or near the top of the list of RCTs' limitations is poor generalizability of many RCT results. In a typical RCT, complex inclusion and exclusion criteria and volunteer bias differentiate those who participate from the broader population with the medical condition being studied. This can create problems in judging whether a patient should be offered a treatment that was effective in a RCT.
Suppose a clinician has memorized or looks up the inclusion and exclusion criteria of a potentially relevant RCT and comprehensively compares those criteria to her or his current clinic patient. The patient will almost certainly be found to differ in some ways from a hypothetical average participant in the RCT. More realistically, in day-to-day clinical work this task of comparing a patient to a RCT's population is often handled in an informal and intuitive way: 'My patient is generally similar to the RCT population on several salient criteria that I recall or have quickly looked up. I see no major contraindications, and I think we can proceed'. This process will be more complicated for patients whose clinical situation is an 'edge case' near the margins of eligibility on several parameters. Such patients might be too unlike the average patient enrolled in the RCT for the trial's results to be relevant. Are clinicians doing an adequate job judging if their patient is similar enough to those who benefited in a clinical trial for the results to be applicable?
Laffin and colleagues 1 asked whether a formal modeling approach might improve the situation. They are to be congratulated on envisioning and developing a means of assessing the similarity of the participants in an RCT and individual patients. Their approach is rooted in calculating the distance in the mathematical sense -Euclidian distance -between a hypothetical average participant in a RCT and a patient who might be considered for treatment based on that RCT's results. In the example provided in their paper, a score ('data zone score') representing this distance for a patient is calculated using six clinically important variables from the Systolic Blood Pressure Intervention Trial (SPRINT). Each variable's impact is weighted according to the strength of its association with the primary SPRINT outcome. The score falls in one of three categories representing the degree of similarity between the person under consideration and the hypothetical average participant in SPRINT.
The authors' approach is clever, and the work is important and timely addressing at least two important problems. The first problem addressed by this work is how to consider formally the similarity of a patient to the average participant in a previously completed RCT. Although pragmatic RCTs are becoming more common, most clinical trials are anything but pragmatic, with highly filtered enrollment and limited generalizability. This new work provides a theoretical framework for measuring how similar a patient is to the population of a RCT. In addition, it reduces the theoretical framework to practice in the form of an algorithm so that the framework can be applied. Moreover, the authors' analysis suggests that their new score relates to patients' outcomes.
The second problem addressed is the limits of human memory. There are now myriad RCTs published annually, and it is increasingly unlikely that clinicians can remember the entry and exclusion criteria for the many RCTs that guide their practice. I wonder whether busy clinicians look up the inclusion and exclusion criteria for trial after trial during their day, matching these against their patients. Irrespective of what clinicians do now, technology might provide some advantages. One can imagine the eventual development of an electronic health record-embedded algorithm automatically alerting clinicians to quantified similarity between a patient and the average participant who benefited in a practice-changing RCT. Such computer assistance could help address well-known gaps in the implementation of RCT findings.
As people take note of this interesting new work, I predict suggestions for a next iteration of this concept will emerge on Twitter and in other places, perhaps. We should welcome those ideas; they could inspire the authors or others to continue this work, which is to be hoped. For now, let us recognize the imagination and initiative of these investigators to try to improve the casual and haphazard usual approach to comparing patients to RCT participants. The potential usefulness of this novel approach seems obvious in retrospect. Looking obvious in retrospect is a hallmark of a good idea.
A caveat mentioned by the authors is worth amplifying. If a patient would have been excluded from a RCT on safety grounds, her or his data zone score might not encode that information, depending on the variables included in the score. A participant very similar to the average trial participant in terms of six clinically relevant variables could nonetheless be definitively unsuitable for the treatment due to a single, compelling safety concern. In clinical practice, the principle of primum non nocere prompts us to be alert for contraindications. A hypothetical disadvantage of data zones is that a contraindication to RCT participation could go unnoticed if the data zone score is used as a sole means of adjudicating similarity to the RCTs' participants. One can imagine a future implementation in which contraindications and safety-related RCT exclusion criteria are weighted in a way that drastically reduces the score for similarity. Or perhaps a more elegant solution to this potential problem will reveal itself over time.
There are now many scores available to cardiologists to help predict what will happen to their patients. This score seems different in intent from others I have seen, and I hope it will stimulate other new thinking about how to apply the results of RCTs to patients. Emphasis on making the score very easy to use would be a logical next step, in addition to vetting whether this can be extended successfully to other clinical trials. I will close by noting that sharing of clinical trial data is expanding, fostered by novel technical solutions to privacy challenges inherent in sharing. The feed-forward effect of sharing on human progress is highlighted by technical improvements for data sharing modeled and tested using newly available clinical trial data.
2 As clinical trial data sharing continues to expand, we can expect a concomitant increase in clever and impactful analyses, and we should be on the lookout for how they might improve our practice.
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